Trial
NCT05617313
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Jeffrey Clarke
Collaborators
Merck Sharp & Dohme LLC; Grid Therapeutics
Condition
Non Small Cell Lung Cancer
Intervention
Pembrolizumab
Why stopped
Study did not meet the criteria for continuation after interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-30